AMGN Stock
Amgen Inc. Common Stock
—
Price
Daily closes via Alpaca (IEX); today's point is the latest trade.
Key stats
Valuation
P/E (trailing)25.1
Forward P/E19.2
Price / sales6.1
Price / book15.9
EPS (12 mo)$17.25
Dividend yield3.21%
Beta0.42
Financial health last 12 months
Revenue growth+8.2%
Earnings growth+33.3%
Gross margin74.7%
Net margin+24.1%
Return on equity85.6%
Debt / equity3.76
Hover a figure for what it means.
Analyst ratings Nov 2026 · 42 analysts
Consensus: Hold
Strong buy 6Buy 12
Hold 20Sell 3
Strong sell 1
| Month | Buy | Hold | Sell | Consensus |
|---|---|---|---|---|
| Nov 2026 | 18 | 20 | 4 | Hold |
| Oct 2026 | 18 | 20 | 4 | Hold |
| Sep 2026 | 20 | 20 | 3 | Buy |
| Aug 2026 | 21 | 19 | 3 | Buy |
Latest news
Dividend Investing When Things Go South
SeekingAlpha · 1d ago
Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm
Benzinga · 1d ago
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says
Yahoo · 2d ago
Eli Lilly Stopped Touting Dose Counts. Should You Worry?
Yahoo · 2d ago
Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Yahoo · 2d ago
Headlines from the last 10 days via Finnhub; links open the publisher's article.
Next earnings
No report scheduled in the next 4 months.
Past earnings moves
0 of 1
moved more than expected
| Report | Expected | Actual |
|---|---|---|
| Nov 3, 2026 | ±4.8% | +2.1% |